[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588317":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":25,"responsibleParty":41,"collaborators":25,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":25,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":69,"whyStopped":25,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":25},{"fullName":5,"class":6},"Southeast University, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"the intermittent infusion group","ACTIVE_COMPARATOR","Ceftazidime-avibactam will be administered as 2.5 g q8h by intermittent infusion for 2 h, and the dosage could be adjusted according to the instructions.",[13],"Drug: treatment with CAZ-AVI",{"label":15,"type":16,"description":17,"interventionNames":18},"the continuous infusion group","EXPERIMENTAL","After a loading dose of ceftazidime-avibactam, continuous infusion is administered, with the dose adjustment rules consistent with those of the intermittent infusion group.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","treatment with CAZ-AVI","Randomize subjects to receive CAZ-AVI via either continuous infusion or intermittent infusion. The total daily dose and dosing interval should be determined according to the subject's body weight, renal function, and estimated drug clearance based on standard prescribing guidelines. Regardless of administration method, the same criteria for dose adjustment (including indications for modification and monitoring parameters) must be consistently applied to both control and experimental groups.",[15,9],null,[27],{"name":28,"affiliation":29,"role":30},"Feng jian Xie, MD","Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University","STUDY_CHAIR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},"feng jian Xie, MD","CONTACT","+86-025-83262552","xie820405@126.com",{"name":38,"role":34,"phone":39,"phoneExt":25,"email":40},"Lin lin Hu, PhD","+86-025-83272127","eliza50@sina.com",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Jianfeng Xie","director","100588317","phase-4-a-multicenter-clinical-study-on-the-continuous-vs-intermittent-infusion-of-ceftazidime-avibactam-in-critically-ill-patients-with-severe-infections-100588317",false,"NCT06939829","A Multicenter Clinical Study on the Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","A Prospective, Open-Label, Randomized Controlled, Multicenter Clinical Study on Continuous vs. Intermittent Infusion of Ceftazidime-Avibactam in Critically Ill Patients With Severe Infections","AVIATOR","Inclusion Criteria:\n\n* 18-85 years old, male or female.\n* Patients who are admitted to ICU wards.\n* Patients clinically diagnosed with carbapenem-resistant organism (CRO) infections, and has been commenced on targeted therapy with ceftazidime-avibactam.\n* One or more organ dysfunction criteria in the previous 24 hours i. MAP \\\u003C 60 mmHg for at least 1 hour; ii. Vasopressors required for \\> 4 hours; iii. Respiratory support using supplemental high flow nasal prongs, continuous positive airway pressure, bilevel positive airway pressure or invasive mechanical ventilation for at least 1 hour.\n\niv. Serum creatinine concentration \\> 220 μmol\u002FL or \\>2.49 mg\u002FdL\n\nExclusion Criteria:\n\n* Patient has a known allergy to ceftazidime-avibactam.\n* Patient has received ceftazidime-avibactam for more than 48 hours during current infectious episode.\n* Patient is in severe condition or expected to survive for no more than 48 hours.\n* Patient who receives lung or heart transplant or stem cell transplant.\n* Patient is known or suspected to be pregnant.\n* Patient has previously been enrolled in the current study.\n* Other conditions which are regarded as inappropriate for enrollment.","ALL","18 Years","85 Years",{"count":57,"type":58},1200,"ESTIMATED","INTERVENTIONAL",[61],"PHASE4","The objective of this study is to determine whether continuous infusion of ceftazidime-avibactam (CAZ-AVI) could improve clinical outcomes in critically ill patients compared with intermittent infusion.",[64],"Patients With Critically Ill Infections",[66,67,68],"Ceftazidime-Avibactam","Continuous versus Intermittent Infusion","clinical study","NOT_YET_RECRUITING","2025-04-15",{"date":72,"type":73},"2025-04-23","ACTUAL",{"date":75,"type":58},"2025-05-01",{"date":77,"type":58},"2027-12-31",{"name":5,"class":6}]